Compare Enveric Biosciences Inc (ENVB) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Verisign, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Verisign, Inc. trades at $297.85 (market cap $26.92B). The key difference: Verisign, Inc. is far larger — about 3958.8× Enveric Biosciences Inc's market cap, and Verisign, Inc. pays a 1.09% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Verisign, Inc. for 123 Days on average.
| ENVB | VRSN | |
|---|---|---|
Market Cap | $6.80M | $26.92B |
Volume | 64,867 | 1,921,402 |
Sector | Health | Technology |
52-Week High | $10.80 | $310.00 |
52-Week Low | $1.27 | $211.49 |
Typical Hold Time | 14 Days | 123 Days |
Enterprise Value | -$1.49M | $28.23B |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
VeriSign (VRSN) trades at $294.22, up 0.38% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $348. The company reported strong 2025 results with $1.66 billion in revenue and a net income margin near 50%, though recent quarterly EPS results have been mixed. Positive sentiment is driven by record domain registrations and institutional buying, while an antitrust lawsuit presents a notable risk.
The stock offers upside potential based on analyst targets, supported by stable cash flow and high profitability. Key risks include legal challenges and competitive pressures. The upcoming Q3 2026 earnings report on October 22 will be critical for validating growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
